Literature DB >> 20980775

Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells.

Seema Gupta1, Sabapathi Sathishkumar, Mansoor M Ahmed.   

Abstract

BACKGROUND: Though an increased efficacy of carmustine and temozolomide (TMZ) has been demonstrated by inactivation of O(6)-methylguanine-DNA methyltransferase (MGMT) with O(6)-benzyl-guanine (BG) in human pancreatic tumors refractive to alkylating agents, the regulatory mechanisms have not been explored.
METHODS: The effects of TMZ and BG on apoptosis, cell growth, the mitotic index, cell cycle distribution, and protein expression were studied by TUNEL, cell counting, flow cytometry, and Western blot analysis, respectively.
RESULTS: The wt-p53 human pancreatic tumor cell line Capan-2 and p53-efficient mouse embryonic fibroblasts (MEFs) were more responsive to treatment with TMZ + BG than mutant p53 Capan-1 and p53-null MEFs. S phase delay with a subsequent G2/M arrest was observed in Capans in response to BG + TMZ. The G1-to-S transition delay in Capan-2 was associated with p53-dependent apoptosis and was distinctly different from the presumed mismatch repair (MMR) killing operative during the G2/M arrest. The effect of p53 on BG + TMZ toxicity was supported by a marked change in apoptosis when p53 function was restored/inactivated. There was an early induction of MMR proteins in p53-efficient lines.
CONCLUSION: p53 provokes a classic proapoptotic response by delaying G1-to-S progression, but it may also facilitate cell killing by enhancing MMR-related cell cycle arrest and cell death.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20980775      PMCID: PMC2992636          DOI: 10.1159/000317254

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  52 in total

Review 1.  The DNA damage response: putting checkpoints in perspective.

Authors:  B B Zhou; S J Elledge
Journal:  Nature       Date:  2000-11-23       Impact factor: 49.962

2.  Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

Authors:  Y Wang; J Li; R N Booher; A Kraker; T Lawrence; W R Leopold; Y Sun
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

Review 3.  ATM, a central controller of cellular responses to DNA damage.

Authors:  K K Khanna; M F Lavin; S P Jackson; T D Mulhern
Journal:  Cell Death Differ       Date:  2001-11       Impact factor: 15.828

Review 4.  Cell cycle checkpoint signaling through the ATM and ATR kinases.

Authors:  R T Abraham
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

Review 5.  DNA repair in resistance to alkylating anticancer drugs.

Authors:  B Kaina; M Christmann
Journal:  Int J Clin Pharmacol Ther       Date:  2002-08       Impact factor: 1.366

6.  Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.

Authors:  P Giannakakou; R Robey; T Fojo; M V Blagosklonny
Journal:  Oncogene       Date:  2001-06-28       Impact factor: 9.867

Review 7.  Pathways governing G1/S transition and their response to DNA damage.

Authors:  J Bartek; J Lukas
Journal:  FEBS Lett       Date:  2001-02-16       Impact factor: 4.124

8.  Multifaceted resistance of gliomas to temozolomide.

Authors:  Dora B Bocangel; Sydney Finkelstein; S Clifford Schold; Kishor K Bhakat; Sankar Mitra; Demetrius M Kokkinakis
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

9.  Par-4, a pro-apoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3.

Authors:  Damodaran Chendil; Anindita Das; Swatee Dey; Mohammed Mohiuddin; Mansoor M Ahmed
Journal:  Cancer Biol Ther       Date:  2002 Mar-Apr       Impact factor: 4.742

10.  Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.

Authors:  E Díaz-Rubio; T R J Evans; J Tabemero; J Cassidy; J Sastre; M Eatock; D Bisset; P Regueiro; J Baselga
Journal:  Ann Oncol       Date:  2002-04       Impact factor: 32.976

View more
  5 in total

1.  Thermotherapy enhances oxaliplatin-induced cytotoxicity in human colon carcinoma cells.

Authors:  Xiang-Liang Zhang; An-Bin Hu; Shu-Zhong Cui; Hong-Bo Wei
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

2.  Relationship Between the Expression of O6-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response in Metastatic Pancreatic Adenocarcinoma Treated with FOLFIRINOX.

Authors:  Carole Vitellius; Caroline Eymerit-Morin; Dominique Luet; Lionel Fizanne; Fanny Foubert; Sandrine Bertrais; Marie-Christine Rousselet; François-Xavier Caroli-Bosc
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 3.  Gene therapy in pancreatic cancer.

Authors:  Si-Xue Liu; Zhong-Sheng Xia; Ying-Qiang Zhong
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

Review 4.  Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes.

Authors:  Marie Rouanet; Marine Lebrin; Fabian Gross; Barbara Bournet; Pierre Cordelier; Louis Buscail
Journal:  Int J Mol Sci       Date:  2017-06-08       Impact factor: 5.923

5.  MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX).

Authors:  Kei Kawaguchi; Kentaro Igarashi; Takashi Murakami; Tasuku Kiyuna; Thinzar M Lwin; Ho Kyoung Hwang; Jonathan C Delong; Bryan M Clary; Michael Bouvet; Michiaki Unno; Robert M Hoffman
Journal:  Oncotarget       Date:  2017-07-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.